Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery

By Liao Chun-Hou   Wang Chung-Cheng   Jiang Yuan-Hong  

Toxins, Vol. 8, Iss. 4, 2016-03 ,pp. : 91-91

MDPI

Access to resources Recommend Favorite

Changes in Immunogenicity during the Development of Urinary Bladder Cancer: A Preliminary Study

By Jóźwicki Wojciech   Brożyna Anna A.   Siekiera Jerzy   Slominski Andrzej T.  

International Journal of Molecular Sciences, Vol. 17, Iss. 3, 2016-02 ,pp. : 285-285

MDPI

Access to resources Recommend Favorite

Urinary Bladder Cancer Susceptibility Markers. What Do We Know about Functional Mechanisms?

By Dudek Aleksandra M.   Grotenhuis Anne J.   Vermeulen Sita H.   Kiemeney Lambertus A. L. M.   Verhaegh Gerald W.  

International Journal of Molecular Sciences, Vol. 14, Iss. 6, 2013-06 ,pp. : 12346-12366

MDPI

Access to resources Recommend Favorite

Fucoidan Inhibits the Proliferation of Human Urinary Bladder Cancer T24 Cells by Blocking Cell Cycle Progression and Inducing Apoptosis

By Park Hye Young   Kim Gi-Young   Moon Sung-Kwon   Kim Wun Jae   Yoo Young Hyun   Choi Yung Hyun  

Molecules, Vol. 19, Iss. 5, 2014-05 ,pp. : 5981-5998

MDPI

Access to resources Recommend Favorite

Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature

By Moore David C.   Cohn Joshua A.   Dmochowski Roger R.  

Toxins, Vol. 8, Iss. 4, 2016-03 ,pp. : 88-88

MDPI

Access to resources Recommend Favorite